Shionogi & Co., Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All SH0.F news ›Analyzing Sonoma Pharmaceuticals (NASDAQ:SNOA) & Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)
Posted by Defense World Staff on Oct 19th, 2026 Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) are both healthcare companies, but which is the better…
Bacterial Infectious Diseases Therapeutics Market Gains Momentum as Shionogi Secures US$482 Million U.S. Government Contract for Drug-Resistant Infections
The bacterial infectious diseases therapeutics market is gaining strategic importance as pharmaceutical companies and governments expand efforts to address antibiotic resistance and difficult to treat bacterial infections On August 28 2026…
Japan’s Shionogi acquires America’s IntraBio in USD2bn deal
Cleary Gottlieb Steen & Hamilton, DLA Piper and Kirkland & Ellis have advised on Shionogi’s USD2 billion acquisition of IntraBio, strengthening its rare disease portfolio with AQNEURSA and specialist expertise. Under the agreement signed…
Shionogi's $2B IntraBio Deal Caps a Q3 Where Biopharma Deal Value Held Above Its Five-Year Average
Eli Lilly remained the most active large pharma acquirer, adding two more deals in Q3 to bring its year-to-date total to 13. Beyond that, the quarter was conspicuously quiet for big pharma on the acquisition front — which makes Shionogi's…
Shionogi to acquire IntraBio for $2B
Explore the BridgeTower Media network. 35 publications across 4 industries. Shionogi to acquire IntraBio for $2B Target's Aqneursa drug is the first FDA-approved treatment for ataxia in patients with A-T Shionogi Inc.'s location in Florham…
DLA Piper advises IntraBio on US$2.0 billion acquisition by Shionogi
DLA Piper advised IntraBio Inc. in connection with its entry into a definitive agreement to be acquired by Shionogi Inc., a subsidiary of Shionogi & Co., Ltd., in a transaction that includes US$2 billion in upfront cash consideration. The…
Shionogi makes $2B rare disease play with IntraBio buy
Shionogi has moved to acquire commercial-stage IntraBio for $2 billion upfront just weeks after the Texas-based biotech secured an FDA approval in a rare disease for which there are no other treatments. Just a few weeks ago, IntraBio…
Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition
Shionogi has agreed to acquire IntraBio for $2 billion, in a deal intended to expand the Japanese pharma’s rare disease portfolio with a drug marketed in the U.S. and European Union for neurological manifestations of Niemann-Pick disease…
Shionogi continues rare disease expansion with acquisition of IntraBio
The Pharma Letter
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
biospace.com2
-
law360.com2
-
nippon.com2
-
thepharmaletter.com2
-
biopharmadive.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 22 articles, not a forecast.